Acute Promyelocytic Leukemia
Conditions
Interventions
study group:Oral Tetra-arsenic Tetra-sulphide Formula Plus ATR
control group:EFS
Sponsors
Peking University People's Hospital Address
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed APL by cytomorphology, confirmed also by molecular analysis; 2. To be aged 18 to 71 years; 3. WHO performance status 0-2 included;4.white blood cell at diagnosis <=10*10^9/L; 5. Serum total bilirubin <=3.0 mg/dL (<=51umol/L); 6. Serum creatinine <=3.0 mg/dL (<=260 umol/L); 7.Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. cerebral ischemic; 2. pregnancy; 3. Subjects who cannot sign written informed consent; 4. Significant arrhythmias, EKG abnormalities or neuropathy; 5. Subjects who cannot comply with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Event-free survival (EFS);Rate of cumulative incidence of relaps;Rate of cumulative incidence of relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of hematological complete remission;Overall survival rate;Incidence of hematological and non-hematological toxicity episodes during treatment as assessed by National Cancer Institute Common Toxicity Criteria;Quality of life at the end of induction therapy and at the end of the consolidation course; | — |
Countries
China
Contacts
Public ContactXiao-Jun Huang
Peking University People's Hospital
Outcome results
None listed